Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry E Fields

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Thrombosis and Haemostasis|July 24, 2015
All-cause mortality and use of antithrombotics within 90 days of discharge in acutely ill medical patientsCharles E Mahan, Larry E Fields, Roger M Mills, et al.
Thrombosis Research|October 2, 2013
Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient populationCharles E Mahan, Maxine D Fisher, Roger M Mills, et al.
International Journal of Cardiology|April 23, 2016
Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic strokeMark J Alberts, W Frank Peacock, Larry E Fields, et al.
Clinical Cardiology|January 16, 2015
Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxabanSally Tamayo, W Frank Peacock, Manesh Patel, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 18, 2013
Antithrombotic medication use and bleeding risk in medically ill patients after hospitalizationCharles E Mahan, Alex C Spyropoulos, Maxine D Fisher, et al.
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|July 10, 2014
Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillationGerald V Naccarelli, Riccardo Cappato, Stefan H Hohnloser, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Thrombosis and Haemostasis|July 24, 2015
All-cause mortality and use of antithrombotics within 90 days of discharge in acutely ill medical patientsCharles E Mahan, Larry E Fields, Roger M Mills, et al.
Thrombosis Research|October 2, 2013
Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient populationCharles E Mahan, Maxine D Fisher, Roger M Mills, et al.
International Journal of Cardiology|April 23, 2016
Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic strokeMark J Alberts, W Frank Peacock, Larry E Fields, et al.
Clinical Cardiology|January 16, 2015
Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxabanSally Tamayo, W Frank Peacock, Manesh Patel, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 18, 2013
Antithrombotic medication use and bleeding risk in medically ill patients after hospitalizationCharles E Mahan, Alex C Spyropoulos, Maxine D Fisher, et al.
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|July 10, 2014
Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillationGerald V Naccarelli, Riccardo Cappato, Stefan H Hohnloser, et al.
Pageof 2